Antisense Oligonucleotides Modulate Tau mRNA Splicing
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for neurodegenerative diseases such as Alzheimer's and seizure disorders are inadequate, particularly for individuals who do not respond to anticonvulsants, highlighting the need for effective methods to inhibit Tau expression or modulate its splicing to address these conditions.
Innovation Solution
The development of methods and compounds, including antisense oligonucleotides, to modulate Tau mRNA splicing and expression in cells and animals, specifically targeting the Tau transcript to reduce the 4R:3R tau isoform ratio in the central nervous system, thereby decreasing Tau protein levels and hyperphosphorylation.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current anticonvulsant treatments are used, then seizure control may be achieved in some patients, but treatment effectiveness is inadequate for individuals who do not respond to these medications
Solution Approach 1:
The patent changes the therapeutic parameter from symptomatic management (anticonvulsants) to disease-modifying therapy (Tau expression inhibition). By targeting the underlying pathogenic mechanism - abnormal Tau protein expression and splicing - the treatment achieves effectiveness in patients who failed conventional therapy, thereby improving reliability while expanding adaptability to non-responders.
Solution Approach 2:
The patent introduces antisense oligonucleotides as an intermediary molecule that mediates between the administered drug and the target Tau mRNA. These oligonucleotides specifically bind to Tau pre-mRNA to modulate splicing and reduce 4R Tau isoform production, creating a new therapeutic pathway that bypasses resistance to conventional anticonvulsant mechanisms.
2Reliability
If Tau expression is inhibited or splicing is modulated to reduce 4R:3R tau ratio, then neurodegenerative symptoms are reduced, but the complexity of the treatment approach increases
Solution Approach 1:
The patent extracts and targets the specific pathological element - the abnormal splicing pattern of Tau pre-mRNA that produces excessive 4R Tau isoforms. By using antisense oligonucleotides that specifically bind to splice regulatory sequences, the treatment isolates and corrects the splicing defect without requiring complex multi-target approaches, thereby achieving symptom reduction with a focused mechanism.
Solution Approach 2:
The patent uses synthetic antisense oligonucleotide copies that are complementary to specific sequences in Tau pre-mRNA. These oligonucleotide copies bind to the target RNA and redirect splicing through sequence-specific hybridization, providing a precise and relatively simple method to modulate Tau isoform production without complex device or procedural requirements.
3Adaptability or versatility
If conventional treatments are used for neurodegenerative diseases, then general symptom management is provided, but specific tau-associated pathology is not adequately addressed
Solution Approach 1:
The patent inverts the conventional therapeutic approach by instead of managing symptoms downstream, targeting the upstream cause - abnormal Tau splicing and 4R Tau production. By using antisense oligonucleotides to correct the splicing defect at the RNA level, the treatment addresses the root pathology rather than merely managing downstream neurodegenerative symptoms, thereby achieving disease-modifying effectiveness.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
These methods effectively reduce symptoms associated with tau-associated disorders, including seizures and neurodegenerative diseases, by modulating Tau expression and splicing, potentially slowing disease progression and improving neurodegenerative function.
Implementation Method 1
compounds, including antisense oligonucleotides, to modulate Tau mRNA splicing and expression in cells and animals, specifically targeting the Tau transcript
Data Source
AI summary
Disclosed are methods for modulating splicing of Tau mRNA in an animal with Tau antisense compounds. Also disclosed herein are methods for reducing expression of Tau mRNA and protein in an animal with Tau antisense compounds. Such compounds and methods are useful to treat, prevent, or ameliorate neurodegenerative diseases in an individual in need thereof. Examples of neurodegenerative diseases that can be treated, prevented, and ameliorated with the administration Tau antisense oligonucleotides include Alzheimer's Disease, Fronto-temporal Dementia (FTD), FTDP-17, Progressive Supranuclear Palsy, Chronic Traumatic Encephalopathy, Epilepsy, and Dravet's Syndrome.